Access Pharmaceuticals (ACCP: OTCBB) is an emerging specialty pharma company developing and commercializing propriety products for the treatment and supportive care of cancer patients. MuGard, its FDA approved treatment for oral mucositis, is commercially launched in Europe, and will launch in the US and Asian in 1Q 2010. ProLindac, which is in pivotal clinical trials, is a new and improved version of Sanofi-Aventis’ Eloxatin, a DACH Platinum chemotherapeutic. Thiarabine is in human trials for the treatment of leukemias and lymphomas. Lastly, ACCP has collaborations in the areas of oral insulin and oral human growth hormone, using it’s proprietary Cobalamin based oral drug delivery platform.
Access Pharmaceuticals signs collaborative deal with major pharma company for CobOral insulin
Access Pharmaceuticals (OTCBB: ACCP) said Wednesday it has agreed, with a large undisclosed global pharma company, to test Access' oral insulin formulation for diabetes, based on its CobOral drug delivery technology.
Access said it will provide CobOral insulin to the pharmaceutical company, and it anticipates the completion and delivery of the insulin by the end of the month.
"We continue executing on our broad strategy for unlocking the value of the CobOral and CobaCyte platform technologies through formulation agreements with high-quality partners," said president and CEO of Access Jeffrey Davis.
"We are confident in our technology's ability to improve the existing standard of administering insulin...we believe that successful testing of the oral insulin product can lead to development programs on additional injectable drugs.”
Access recently announced a deal with another biopharmaceutical company to develop an oral version of the undisclosed company's marketed injectable drug for prostate cancer.
Access has already filed supplementary patents covering the use of both of its drug delivery platforms, including CobOral and CobaCyte, with many of the top 100 currently-marketed, injectable drugs. The company said it is continually looking for additional collaborations to turn these injectable drugs into oral formulations.
Access initially focused its CobOral product development program on the oral delivery of insulin and human growth hormone (hGH), two peptides which currently can only be given by injection.
According to the company, a CobOral insulin formulation provided a pharmacological response, or the lowering of blood glucose levels in an animal with diabetes, equivalent to greater than 80% of that achieved by insulin delivered through injection.
Access said that the adaptation of this technology has provided a CobOral HGH formulation that demonstrated "good efficacy", represented by more than 25% improvement in weight gain, when given orally in an animal.
The company's products include MuGard for the management of patients with mucositis and ProLindac, currently in Phase II clinical testing of patients with ovarian cancer, and Thiarabine, a new therapy for certain cancers.